Managed Healthcare Executive September 5, 2024
The private-label biosimilar will be available at an 80% discount off Stelara. Evernorth has not released information about which company will be producing the biosimilar.
Beginning in early 2025, Evernorth Health Services will offer clients and their members a private-label biosimilar of Stelara (ustekinumab). The interchangeable biosimilar will be produced for Evernorth’s affiliate private-label distributor, Quallent Pharmaceuticals, and will have a price that is more than 80% lower than the list price of Stelara. In a press release, Evernorth indicated that this represents an opportunity for significant savings.
Developed by Janssen, a Johnson & Johnson company, Stelara is a high-cost drug with a list price of $13,836 for one month’s supply. In the first half of this year, Stelara generated...
Today's Sponsors
Today's Sponsor